Quintiles, London Genetics Offer Pharmacogenetics Solutions

Quintiles and London Genetics have entered a strategic alliance to offer pharmacogenetics solutions to the biopharmaceutical industry in an effort to advance personalized medicine. The two companies will collaborate to provide pharmacogenetic solutions, including novel biomarker and assay development services, aimed at helping clients access additional resources and speed the delivery of targeted treatments. Financial terms were not disclosed.

“In the New Health, biopharmaceutical companies are under relentless pressure to replenish their product pipelines and deliver safer, more effective medicines to patients in need,” said Thomas Wollman, senior vice president, Quintiles Global Central Laboratories. “Through our alliance with London Genetics, we have world-class expertise to help early adopters of personalized medicine use genomic technologies to improve drug discovery and development, and a networked infrastructure to support those efforts virtually anywhere in the world.”

“Our expertise in pharmacogenetic strategy development, combined with Quintiles’ expertise and infrastructure in biomarker development, gives biopharma companies a powerful ally in harnessing the value of genomic data for drug development,” said Dominique Kleyn, chief executive officer of London Genetics. “Ultimately, our alliance will support biopharma in their interactions with academic partners and the development of personalized medicines.”

Quintiles develops proprietary and novel biomarker tests analyzing genes and proteins that affect cell growth and mutation, and performs these assays at labs in the U.S., Scotland and China. Additionally, Quintiles’ central lab network includes wholly owned facilities in the U.S., Europe, South Africa, India, China, Singapore and Japan, with affiliate labs in Argentina and Brazil. London Genetics works with London-based centers of excellence in genetics research to provide pharmacogenetic solutions. London Genetics helps companies partner with relevant academics and clinicians, to apply genetic knowledge to de-risk clinical trials, design and manage projects, and to access patient cohorts.